- Home
- OBE vs NGNE Comparison
OBE vs NGNE Comparison
Compare OBE & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- NGNE
- Stock Information
- Founded
- OBE 1979
- NGNE 2003
- Country
- OBE Canada
- NGNE United States
- Employees
- OBE N/A
- NGNE N/A
- Industry
- OBE Oil & Gas Production
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- NGNE Health Care
- Exchange
- OBE Nasdaq
- NGNE Nasdaq
- Market Cap
- OBE 391.9M
- NGNE 325.3M
- IPO Year
- OBE N/A
- NGNE N/A
- Fundamental
- Price
- OBE $6.01
- NGNE $19.00
- Analyst Decision
- OBE Buy
- NGNE Strong Buy
- Analyst Count
- OBE 2
- NGNE 7
- Target Price
- OBE $11.50
- NGNE $41.86
- AVG Volume (30 Days)
- OBE 236.1K
- NGNE 140.1K
- Earning Date
- OBE 10-30-2025
- NGNE 08-11-2025
- Dividend Yield
- OBE N/A
- NGNE N/A
- EPS Growth
- OBE N/A
- NGNE N/A
- EPS
- OBE N/A
- NGNE N/A
- Revenue
- OBE $508,849,882.00
- NGNE N/A
- Revenue This Year
- OBE N/A
- NGNE N/A
- Revenue Next Year
- OBE N/A
- NGNE N/A
- P/E Ratio
- OBE N/A
- NGNE N/A
- Revenue Growth
- OBE 1.49
- NGNE N/A
- 52 Week Low
- OBE $3.88
- NGNE $6.88
- 52 Week High
- OBE $6.53
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- OBE 52.32
- NGNE 44.43
- Support Level
- OBE $5.87
- NGNE $18.37
- Resistance Level
- OBE $6.25
- NGNE $20.72
- Average True Range (ATR)
- OBE 0.20
- NGNE 1.16
- MACD
- OBE -0.01
- NGNE 0.00
- Stochastic Oscillator
- OBE 39.00
- NGNE 36.76
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.